Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type abstract
PMID
Authors Elie G. Dib; Michael Rothe; Pam K. Mangat; Elizabeth Garrett-Mayer; Dustin Bivins; Mark Gitau; Apar K. Ganti; Arthur Winer; Vijay Suhag; Darryl Outlaw; Michael J. Hall; Olatunji B. Alese; Reza Nazemzadeh; Evan Pisick; Fengting Yan; Navid Hafez; Carmen J. Calfa; Lex Leonhardt; David DeRemer; Abigail Gregory; Dominique C. Hinshaw; Gina N. Grantham; Susan Halabi; Richard L. Schilsky
Title Abstract CT228: Talazoparib (Tala) in patients (pts) with solid tumors with ATM alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Journal Vol Issue Date Pages Journal Short Title
Cancer Research 85 8_Supplement_2 April 15, 2025
URL https://aacrjournals.org/cancerres/article/85/8_Supplement_2/CT228/761477/Abstract-CT228-Talazoparib-Tala-in-patients-pts`
Abstract Text Background: TAPUR is a phase II basket study evaluating antitumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with ATM mutation (mut) or deletion (del) treated with Tala are reported. Methods: Eligible pts had metastatic solid tumors, measurable disease, ECOG performance status (PS) 0-2, adequate organ function, and no standard treatment (tx) options. Genomic testing was performed in CLIA-certified, CAP-accredited site selected labs. Pts received 1 mg of Tala orally daily until disease progression. Low accruing histology-specific cohorts with ATM alterations were collapsed into 1 histology-pooled cohort for analysis. Primary endpoint was disease control (DC) per investigator defined as complete or partial response (PR) or stable disease (SD) of at least 16+ weeks (wks) duration (SD16+) per RECIST v1.1. The hypothesized null DC rate of 15% was evaluated by a 1-sided exact binomial test (alpha 0.10; 82% power). Secondary endpoints were progression-free survival (PFS), overall survival (OS), objective response (OR), duration of response (DOR) and SD, and safety. Results: 29 pts with nine different solid tumors with ATM mut (n=28) or del (n=1) were enrolled. 1 pt was not evaluable for efficacy. Table shows demographics, outcomes, and toxicity. 2 PR (lung and thyroid) and 10 SD16+ (pancreas [3], prostate [2], colon, breast, kidney, rectum, stomach, thyroid) were observed in pts with ATM mut for a DC rate of 41% (1-sided 90% CI, 29 to 100) and an OR rate of 7% (95% CI, 1 to 23). The null DC rate was rejected (p=0.0005). The pt with PR and lung cancer is still on tx and has exceeded 73 wks on study as of October 2024. 8 pts had ≥1 grade 3-4 tx-related adverse event (AE). No tx-related serious AE were reported. Conclusions: Tala met prespecified criteria to declare a signal of activity in pts with solid tumors with ATM mut.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ATM mutant Advanced Solid Tumor predicted - sensitive Talazoparib Phase II Actionable In a Phase II trial (TAPUR), Talzenna (talazoparib) treatment resulted in a disease control rate of 41% and an objective response rate of 7% in advanced solid tumor patients harboring ATM mutation (n=28) or deletion (n=1) with 1 partial response in a thyroid cancer patient and 1 partial response in a lung cancer patient ongoing at 73 weeks (Cancer Res (2025) 85 (8_Supplement_2): CT228). detail...